57,222 trials (keyword fallback)
Mouth Neoplasms · Head and Neck Neoplasms · Tongue Neoplasms
Primary: Percent (%) Change in Levels of pS6, pAKt473, and Ki-67 — -60.60; -67.24; -31.48; 100.00 percentage of change from baseline
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Head and Neck Squamous Cell Carcinoma
Primary: Percentage of Patients Alive and Free of Progression at 6 Months — 27 percentage of patients
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Head and Neck Squamous Cell Carcinoma · Malignant Solid Neoplasm
Primary: Phase I: The Recommended Phase II Dose Determenation. Phase II: Overall Response Rate (ORR) and Progression Free Survival (PFS) — 40 mg
Squamous Cell Carcinoma of the Head and Neck Cancer
Primary: Progression-free Survival (PFS) Time: Independent Read Assessments — 1.5; 1.9 months — p=0.793
Head and Neck Cancer
Primary: Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03…
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Primary: Pain-reduction Effects of Adding Venlafaxine to a Regimen of Gabapentin and Methadone to Control Pain During and After Chemoradiation — 8; 13; 39; 40 scores on a scale
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
Head and Neck Cancer · Squamous Cell Cancer
Primary: Participant Response Rate — 7 Participants
Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Laryngeal Verrucous Carcinoma
Primary: Mean Percent Change in p16 Methylation (% CpG Sites Methylated) in Tumor Tissue After Soy Isoflavone — 4.9 Percent change — p=<0.005
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Nasal Cavity
Primary: Overall Survival: Time From Randomization to Death From Any Cause — 74.9; 72.8 percentage of participants — p=0.68
Head and Neck Basaloid Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.8; 3.7 months — p=.04
Metastatic Squamous Cell Carcinoma of the Hypopharynx · Metastatic Squamous Cell Carcinoma of the Larynx · Metastatic Squamous Cell Carcinoma of the Oral Cavity
Primary: Progression Free Survival (PFS) — 6.08; 4.4 months
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants